These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2279251)

  • 21. Comparative effects of ibopamine and captopril in mild congestive heart failure. Focus on the long-term effects of inodilation on ventricular arrhythmias.
    Cocchieri M; Alunni GF; Del Favero A; Fortunati F; Bardelli G; Capponi EA; Regi L; Boschetti E
    Cardiology; 1990; 77 Suppl 5():36-42. PubMed ID: 2126222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of ibopamine in congestive heart failure.
    van Veldhuisen DJ; Girbes AR; Crijns HJ; Smit AJ; de Graeff PA; Lie KI
    J Auton Pharmacol; 1990; 10 Suppl 1():s115-21. PubMed ID: 1983005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure.
    Lieverse AG; Girbes AR; Van Veldhuisen DJ; Smit AJ; Zijlstra JG; Meijer S; Lie KI; Reitsma WD
    Eur Heart J; 1995 Jul; 16(7):937-42. PubMed ID: 7498209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of ibopamine therapy in congestive heart failure. Ibopamine cohort study: baseline and 1-year results.
    Sher D; Licciardello L; Ferrari V; Sirtori F; Cesana B
    Arzneimittelforschung; 1991 Apr; 41(4):402-9. PubMed ID: 1859514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and autonomic effects of ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
    Szabó BM; van Veldhuisen DJ; van der Burgh PH; Kruik J; Girbes AR; Lie KI
    J Card Fail; 1996 Sep; 2(3):185-92. PubMed ID: 8891856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study.
    Alicandri C; Fariello R; Boni E; Zaninelli A; Muiesan G
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S77-82. PubMed ID: 2483444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure.
    Itoh H; Taniguchi K; Tsujibayashi T; Koike A; Sato Y; Nakamura S
    Cardiology; 1992; 80(5-6):356-66. PubMed ID: 1451123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ibopamine--how should it be used?
    Bussmann WD; Wienhöfer K; Frik R
    Cardiology; 1988; 75 Suppl 1():126-37. PubMed ID: 3069210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group.
    Brouwer J; van Veldhuisen DJ; Man in 't Veld AJ; Dunselman PH; Boomsma F; Haaksma J; Lie KI
    J Am Coll Cardiol; 1995 Oct; 26(4):983-90. PubMed ID: 7560628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ibopamine--acute hemodynamic, renal and neurohumoral effects].
    Wehling M; Theisen K
    Z Kardiol; 1991; 80 Suppl 8():67-9. PubMed ID: 1686694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibopamine and survival in severe congestive heart failure: PRIME II.
    Massel D
    Lancet; 1997 Jul; 350(9071):147. PubMed ID: 9228992
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of ibopamine in the treatment of heart failure.
    Taylor SH; Cicchetti V
    Am Heart J; 1990 Dec; 120(6 Pt 2):1583-90. PubMed ID: 1978982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological profile of ibopamine. A summary of experiments on anaesthesized dogs.
    Marchetti GV
    Cardiology; 1990; 77 Suppl 5():22-9. PubMed ID: 1980631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haemodynamic evaluation of ibopamine in severe congestive heart failure.
    Reffo GC; Turrin M; Gabellini A; Forattini C
    Eur J Clin Pharmacol; 1984; 26(1):19-22. PubMed ID: 6714289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure.
    Dei Cas L; Metra M; Visioli O
    Am J Cardiol; 1992 Sep; 70(6):629-34. PubMed ID: 1354938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibopamine does not affect insulin resistance in patients with type I diabetes.
    Benzi L; Sabino F; Ciccarone AM; Cecchetti P; Di Cianni G; Cicchetti V; Navalesi R
    Cardiology; 1990; 77 Suppl 5():63-6. PubMed ID: 2279254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug of the month. Ibopamine (Scandine, Idopamil)].
    Scheen AJ
    Rev Med Liege; 1994 Jun; 49(6):365-6. PubMed ID: 8047755
    [No Abstract]   [Full Text] [Related]  

  • 38. Absence of proarrhythmic effects of ibopamine in patients with congestive heart failure.
    Caponnetto S; Terrachini V; Canale C; Bruzzone F; Licciardello L; Marchetti GV
    J Cardiovasc Pharmacol; 1989; 14 Suppl 8():S104-10. PubMed ID: 2483435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ibopamine in treatment of mild heart failure, a comparison with hydrochlorothiazide].
    Kleber FX; Thyroff-Friesinger U
    Z Kardiol; 1991; 80 Suppl 8():113. PubMed ID: 1796629
    [No Abstract]   [Full Text] [Related]  

  • 40. Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure.
    Gavazzi A; Mussini A; Bramucci E
    Arzneimittelforschung; 1986 Feb; 36(2A):366-70. PubMed ID: 3707652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.